516 patents
Page 6 of 26
Utility
Tricyclic Heterocycles As FGFR Inhibitors
5 Jan 23
Robert Swyka, Evan Styduhar, Xin Li, Oleg Vechorkin, Wenqing Yao
Filed: 8 Jun 22
Utility
Tricyclic Heterocycles As FGFR Inhibitors
5 Jan 23
Xin Li, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Wenqing Yao
Filed: 8 Jun 22
Utility
Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors
5 Jan 23
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
Filed: 13 Jan 22
Utility
Pyrazolopyrimidine compounds and uses thereof
3 Jan 23
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
Filed: 23 Apr 21
Utility
Topical Treatment of Vitiligo by a Jak Inhibitor
29 Dec 22
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 8 Jul 22
Utility
AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS
29 Dec 22
Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
Filed: 24 May 21
Utility
Derivatives of an FGFR Inhibitor
29 Dec 22
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Ming Tao, Jason Boer
Filed: 22 Jul 22
Utility
Heterocyclic compounds as immunomodulators
27 Dec 22
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Filed: 11 Sep 20
Utility
Bicyclic heterocycles as FGFR inhibitors
20 Dec 22
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liang Lu, Wenqing Yao, Chunhong He, Fenglei Zhang
Filed: 28 Jan 21
Utility
Spiro compounds as inhibitors of KRAS
20 Dec 22
Disclosed are spirocyclic compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and treating cancer, and pharmaceutical compositions comprising such compounds.
Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao
Filed: 20 Jan 21
Utility
HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
15 Dec 22
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
James D. Rodgers, Stacey Shepard
Filed: 8 Mar 22
Utility
Hetero-bicyclic Inhibitors of Kras
8 Dec 22
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds.
Alexander Sokolsky, Chang Min, Xiaozhao Wang, Wenqing Yao
Filed: 28 Apr 22
Utility
JAK1 Pathway Inhibitors for the Treatment of Prurigo Nodularis
1 Dec 22
This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.
Paul Smith, Kurt Andrew Brown
Filed: 3 May 22
Utility
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
1 Dec 22
This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
Krishna Vaddi
Filed: 20 Dec 21
Utility
Topical Formulation for a Jak Inhibitor
1 Dec 22
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Ruxolitinib formulation for reduction of itch in atopic dermatitis
29 Nov 22
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 4 Sep 20
Utility
Salts of an LSD1 inhibitor and processes for preparing the same
29 Nov 22
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 12 Mar 21
Utility
Topical Formulation for a Jak Inhibitor
24 Nov 22
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 25 Mar 22
Utility
Salts of a Pim kinase inhibitor
22 Nov 22
The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
Zhongjiang Jia, Ganfeng Cao, Qiyan Lin, Yongchun Pan, Lei Qiao, Vaqar Sharief, Chongsheng Eric Shi, Michael Xia, Changsheng Zheng, Qun Li
Filed: 13 Jan 21
Utility
Multispecific Binding Moieties Comprising Novel PD-1 Binding Domains
17 Nov 22
The present disclosure relates to multispecific binding moieties comprising novel PD-1 binding domains that have a higher binding affinity for human PD-1 than a reference PD-1 binding domain.
Simon Edward PLYTE, Patrick MAYES, Horacio G. NASTRI, Shaun M. STEWART
Filed: 30 Mar 22